MediciNova, Inc. is a biopharmaceutical company that develops small molecule treatments for serious diseases with unmet medical needs. Its focus includes the development of MN-166 for multiple neurological disorders and substance addiction, MN-221 for asthma, MN-001 for fibrotic diseases, and MN-029 for solid tumor cancers. It has collaboration agreements with several well-known pharmaceutical companies.